Effect of Citalopram on Health status, anxiety and depression in patients with chronic Obstructive pulmonary disease: a pilot study

ISRCTN	ISRCTN41544517
DOI	https://doi.org/10.1186/ISRCTN41544517
Secondary identifying numbers	N/A

Submission date: 07/08/2007
Registration date: 21/04/2008
Last edited: 11/10/2017

Recruitment status: No longer recruiting
Overall study status: Completed
Condition category: Respiratory

Prospectively registered

Protocol

Statistical analysis plan

Results

Individual participant data

Record updated in last year

Plain English summary of protocol

Not provided at time of registration

Contact information

Dr Christian P Subbe
Scientific

77 Brook Lane
Chester
LL13 7TD
United Kingdom

Phone	+44 (0)1978 291100
Email	csubbe@hotmail.com

Study information

Study design	Single-centre randomised controlled trial
Primary study design	Interventional
Secondary study design	Randomised controlled trial
Study setting(s)	Hospital
Study type	Treatment
Participant information sheet	Not available in web format, please use the contact details to request a patient information sheet
Scientific title	Effect of Citalopram on Health status, anxiety and depression in patients with chronic Obstructive pulmonary disease: a pilot study
Study acronym	ECHO
Study objectives	Chronic obstructive pulmonary disease (COPD) sufferers often experience a vicious circle of breathlessness and anxiety. These symptoms commonly lead to reduced physical activity, progressive loss of fitness, increasing social isolation and depression (which often goes undiagnosed). If this circle could be broken improved physical functioning and quality of life might result.
Ethics approval(s)	North Wales Health Authority Research Ethics Committee, 05/02/2003
Health condition(s) or problem(s) studied	Chronic obstructive pulmonary disease (COPD)
Intervention	Matching oral citalopram 20 mg and placebo, starting with half a tablet once per day for two weeks, then one tablet per day for the remaining weeks with monthly follow up for three months and a two week period of half a tablet per day prior to discontinuation of treatment.
Intervention type	Drug
Pharmaceutical study type(s)
Phase	Not Applicable
Drug / device / biological / vaccine name(s)	Citalopram
Primary outcome measure	Health-related quality of life, measured using St Georges Respiratory Questionnaire at baseline and 3 months
Secondary outcome measures	1. Depression and anxiety, measured using the Hospital Anxiety and Depression Score (HADS) at baseline and 3 months 2. Depression and anxiety, measured using the Depression in Medical Illness, a 10-item questionnaire (DM-10) at baseline and 3 months Additionally at baseline, 1, 2 and 3 months a structured side effect profile was checked.
Overall study start date	01/08/2003
Completion date	01/08/2004

Eligibility

Participant type(s)	Patient
Age group	Adult
Sex	Both
Target number of participants	20
Key inclusion criteria	1. Diagnosis of COPD 2. Clinical diagnosis of anxiety or depression 3. Adults of either sex
Key exclusion criteria	1. Severe ischaemic heart disease 2. On treatment for anxiety or depression 3. Terminal illness
Date of first enrolment	01/08/2003
Date of final enrolment	01/08/2004

Locations

Countries of recruitment

United Kingdom
Wales

Study participating centre

77 Brook Lane

Chester
LL13 7TD
United Kingdom

Sponsor information

North East Wales NHS Trust (UK)
Hospital/treatment centre

Wrexham Maelor Hospital
Croesnewydd Road
Wrexham
LL13 7TD
Wales
United Kingdom

Phone	+44 (0)1978 291100
Email	csubbe@hotmail.com
Website	http://www.newalesnhstrust.org.uk/
"ROR"	https://ror.org/03awsb125

Funders

Funder type

Government

North East Wales NHS Trust (UK) - Research and Development Fund

No information available

Results and Publications

Intention to publish date
Individual participant data (IPD) Intention to share	No
IPD sharing plan summary	Not provided at time of registration
Publication and dissemination plan	Not provided at time of registration
IPD sharing plan

Editorial Notes

11/10/2017: No publications found, verifying study status with principal investigator.